Review Note
Last Update: 01/29/2025 03:22 AM
Current Deck: ACG Part 2::Cardiac SSU
PublishedCurrently Published Content
Front
SS_CS 1.17 Outline the issues related to the care of patients undergoing cardiopulmonary bypass, including:
• Anticoagulation during cardiopulmonary bypass and point-of-care and laboratory methods of monitoring anticoagulation
Back
- POCT Activated Clotting Time (ACT) >480 to institute CPB
- 300-400IU/kg total body weight
- Effects of heparin: hyperkalemia, hypotension, various effects on platelets
- Hypotension due to release of histamine, cGMP, NO and Ca inhibition
- Reduced macroaggregate platelet formation, increased activation and consumption of platelets while on CPB, changes to platelet morphology
No published tags.
Pending Suggestions
No pending suggestions for this note.